Delving into the Latest Updates on Phleum pratense pollen allergy immunotherapy(HAL Allergy Holding BV) with Synapse

Overview

Basic Info

Drug Type

Allergen extract

Synonyms

Phleum pratense pollen allergy vaccine, Sublivac Fix Grasses, SUBLIVAC FIX Phleum pratense

Target-

Action

modulators

Mechanism

Immunomodulators

Therapeutic Areas

Immune System DiseasesInfectious DiseasesEye Diseases+ [3]

Active Indication-

Inactive Indication

Originator Organization

HAL Allergy Holding BV

Active Organization-

Inactive Organization

HAL Allergy Holding BV

HAL Allergy BV

License Organization-

Drug Highest PhasePendingPhase 3

First Approval Date-

Regulation-

Login to view timeline

The purpose of this study is to assess safety, tolerability and demonstrate a dose response signal using Total Symptom Score (TSS), based on challenges with grass pollen in an Environmental Exposure Chamber (EEC), followed by estimation of the minimum effective dose of SUBLIVAC FIX Phleum (SP) after 10 months of treatment compared to placebo.
The study has 4 treatment groups: 3 different doses of SP and placebo will be tested.

Start Date01 Sep 2015

Sponsor / Collaborator

HAL Allergy Holding BV

EUCTR2010-021235-13-DE

/ Not yet recruitingNot Applicable

A randomized, double-blind, placebo-controlled study to determine safety, tolerability and the optimal effective dose of SUBLIVAC FIX Phleum pratense in patients with allergic rhinitis/rhinoconjunctivitis caused by grass pollen - SUBLIVAC FIX Phleum pratense DT/DRF

Start Date04 Sep 2012

Sponsor / Collaborator-

NCT00422149

/ CompletedPhase 3

Twin SUBLIVAC® Grasses Clinical Efficacy Study

To show that treatment with SUBLIVAC® Grasses is clinically effective by means of reduction in allergic symptoms and/or use of allergic symptomatic medication in subjects suffering from IgE mediated allergic complaints triggered by grass pollen.

Start Date01 Sep 2006

Sponsor / Collaborator

HAL Allergy Holding BV

100 Clinical Results associated with Phleum pratense pollen allergy immunotherapy(HAL Allergy Holding BV)

Login to view more data

100 Translational Medicine associated with Phleum pratense pollen allergy immunotherapy(HAL Allergy Holding BV)

Login to view more data

100 Patents (Medical) associated with Phleum pratense pollen allergy immunotherapy(HAL Allergy Holding BV)

Login to view more data

100 Deals associated with Phleum pratense pollen allergy immunotherapy(HAL Allergy Holding BV)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Conjunctivitis, Allergic	Phase 3	Belgium	HAL Allergy Holding BV	01 Sep 2006
Conjunctivitis, Allergic	Phase 3	Germany	HAL Allergy Holding BV	01 Sep 2006
Conjunctivitis, Allergic	Phase 3	Netherlands	HAL Allergy Holding BV	01 Sep 2006
Conjunctivitis, Allergic	Phase 3	Poland	HAL Allergy Holding BV	01 Sep 2006
Rhinitis, Allergic, Seasonal	Phase 3	Belgium	HAL Allergy Holding BV	01 Sep 2006
Rhinitis, Allergic, Seasonal	Phase 3	Germany	HAL Allergy Holding BV	01 Sep 2006
Rhinitis, Allergic, Seasonal	Phase 3	Netherlands	HAL Allergy Holding BV	01 Sep 2006
Rhinitis, Allergic, Seasonal	Phase 3	Poland	HAL Allergy Holding BV	01 Sep 2006
AIDS-Related Complex	Phase 2	Canada	HAL Allergy Holding BV	01 Sep 2015
Oral allergy syndrome	Phase 2	Canada	HAL Allergy Holding BV	01 Sep 2015

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data